Recently, a phase III clinical trial with a selective estrogen receptor modulator Toremifene, showed a significant reduction in new vertebral fractures in men with prostate cancer receiving androgen ablation therapy [11, 14]. This evidence concerns the gene ESR1 and prostate carcinoma.